Core Viewpoint - The new regulations on Xiaohongshu (Little Red Book) have led to Swisse removing all product links from its official flagship store, significantly impacting its marketing strategy in China, particularly for its "blue hat" certified health products [1][10]. Group 1: Impact of New Regulations - The new regulatory framework prohibits the promotion of all "blue hat" certified health products on Xiaohongshu, which includes various health supplements and infant formula, effectively closing the marketing channel that Swisse relied on [1][10]. - Swisse's growth in China has heavily depended on online platforms, with its product line contributing approximately 70.6% to the adult nutrition and care segment sales, indicating a strong reliance on e-commerce and content platforms [4]. - The new rules are expected to hinder Swisse's marketing efforts, particularly for its domestic "blue hat" products, which are now unable to be promoted through content platforms [10][12]. Group 2: Marketing Strategies and Challenges - Swisse has built a highly industrialized "grass-planting" model on Xiaohongshu, utilizing a mix of influencers to create a robust word-of-mouth ecosystem, which is now threatened by the new regulations [5][6]. - The brand's marketing strategy has led to significant sales growth, with a reported 166% increase in sales for its K2 calcium product, showcasing the effectiveness of its previous marketing efforts [7]. - The new regulations may force Swisse to shift its marketing focus towards its overseas product line, which, while not directly affected by the new rules, faces increased scrutiny and potential limitations in promotional activities [11][12]. Group 3: Future Outlook and Industry Trends - The new regulations signify the beginning of a "post-grass-planting" era for health products, indicating a shift in marketing dynamics across various platforms, not just Xiaohongshu [13][16]. - Brands will need to adapt to higher compliance costs and a more complex marketing landscape, with only a small percentage likely to invest in new strategies to navigate these changes [13][14]. - The overall impact of these regulations on Swisse's parent company, Health and Happiness Group, could be more complex, as the company has already faced financial challenges, including a reported net loss in 2024 [14][15].
Swisse的“蓝帽子难红”